These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 32108046)

  • 1. Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution.
    Yanaka K; Guillien A; Soumagne T; Benet J; Piliero N; Picard F; Pison C; Sitbon O; Bouvaist H; Degano B
    Eur Respir J; 2020 Jun; 55(6):. PubMed ID: 32108046
    [No Abstract]   [Full Text] [Related]  

  • 2. Living With Severe Pulmonary Arterial Hypertension Without an Infusion Pump? Selexipag has a Role to Play.
    Lázaro Salvador M; Akerström F; Escribano Subías P; Berenguel Senén A; Martinez Mateo V; Rodriguez Padial L
    Arch Bronconeumol (Engl Ed); 2019 Feb; 55(2):102-103. PubMed ID: 30060983
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of an implantable wireless pulmonary pressure monitor during transition of therapy in pulmonary arterial hypertension.
    Airhart S; Verlinden N; Badie N; Raina A; Benza R
    J Heart Lung Transplant; 2019 Feb; 38(2):227-230. PubMed ID: 30691597
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of the Prostacyclin Receptor Agonist Selexipag in Patients With Pulmonary Arterial Hypertension Associated With Eisenmenger Syndrome.
    Demerouti EA; Karyofyllis P; Apostolopoulou SC
    Can J Cardiol; 2021 Aug; 37(8):1286-1288. PubMed ID: 33539988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selexipag for the treatment of pulmonary arterial hypertension.
    Genecand L; Wacker J; Beghetti M; Lador F
    Expert Rev Respir Med; 2021 May; 15(5):583-595. PubMed ID: 33382345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transition from intravenous treprostinil to enteral selexipag in an infant with pulmonary arterial hypertension.
    Koo R; Lo J; Bock MJ
    Cardiol Young; 2019 Jun; 29(6):849-851. PubMed ID: 31379316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series.
    Fanous SM; Janmohamed M
    Am J Health Syst Pharm; 2018 Dec; 75(23):1877-1881. PubMed ID: 30301721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-Center Experience Using Selexipag in a Pediatric Population.
    Gallotti R; Drogalis-Kim DE; Satou G; Alejos J
    Pediatr Cardiol; 2017 Oct; 38(7):1405-1409. PubMed ID: 28702718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.
    Berlier C; Schwarz EI; Saxer S; Lichtblau M; Ulrich S
    Lung; 2019 Jun; 197(3):353-360. PubMed ID: 30963265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension.
    Galiè N; Gaine S; Channick R; Coghlan JG; Hoeper MM; Lang IM; McLaughlin VV; Lassen C; Rubin LJ; Hsu Schmitz SF; Sitbon O; Tapson VF; Chin KM
    Adv Ther; 2022 Jan; 39(1):796-810. PubMed ID: 34727317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy.
    Hardin EA; Chin KM
    Drug Des Devel Ther; 2016; 10():3747-3754. PubMed ID: 27895464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
    Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
    J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyroid Dysfunction in Patients with Pulmonary Artery Hypertension (PAH): The Effect of Therapies Affecting the Prostanoid Pathway.
    Menon AA; Sahay S; Braverman LE; Farber HW
    Lung; 2019 Dec; 197(6):761-768. PubMed ID: 31696306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful transition from intravenous epoprostenol to oral selexipag and inhaled iloprost in a case of severe pulmonary arterial hypertension associated with systemic lupus erythematosus.
    Saiki C; Kashiwado Y; Yokoyama T; Ayano M; Imabayashi K; Kawano S; Higashioka K; Kimoto Y; Fukata M; Mitoma H; Ono N; Arinobu Y; Akashi K; Horiuchi T; Niiro H
    Mod Rheumatol Case Rep; 2022 Jun; 6(2):183-188. PubMed ID: 35134204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension.
    Parikh KS; Doerfler S; Shelburne N; Kennedy K; Whitson J; Dahhan T; Fortin T; Rajagopal S
    J Cardiovasc Pharmacol; 2020 Apr; 75(4):299-304. PubMed ID: 31934912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and persistence with selexipag in pulmonary arterial hypertension in the real-life setting.
    Del Pozo R; Blanco I; López-Meseguer M; Escribano-Subías P; Cruz Utrilla A
    Eur J Intern Med; 2023 May; 111():140-142. PubMed ID: 36720652
    [No Abstract]   [Full Text] [Related]  

  • 17. Selexipag (Uptravi) for pulmonary arterial hypertension.
    Med Lett Drugs Ther; 2016 Feb; 58(1488):21-3. PubMed ID: 26859660
    [No Abstract]   [Full Text] [Related]  

  • 18. Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension.
    Furukawa A; Tamura Y; Iwahori H; Goto M; Ohashi N; Okabe T; Kawamura A
    BMC Pulm Med; 2017 Oct; 17(1):135. PubMed ID: 29073911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of selexipag for the treatment of pulmonary hypertension.
    Panagiotidou E; Boutou A; Pitsiou G
    Expert Opin Pharmacother; 2021 Jan; 22(1):29-36. PubMed ID: 32867545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The selective PGI2 receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats.
    Honda Y; Kosugi K; Fuchikami C; Kuramoto K; Numakura Y; Kuwano K
    PLoS One; 2020; 15(10):e0240692. PubMed ID: 33057388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.